Drug Establishment Licence Renewal in Canada: Timeline, Fees, and Why Applications Get Rejected

A Drug Establishment Licence expires at midnight on its anniversary date. There’s no grace period written into the Food and Drug Regulations, no automatic extension, and no courtesy reminder from Health Canada letting you know it’s coming. For any establishment in Canada that manufactures, imports, packages, or distributes regulated pharmaceuticals, that expiry date is a hard stop — and missing it can halt operations entirely.

Most DEL holders know the annual renewal exists. Fewer understand the mechanics that determine whether that renewal goes smoothly or turns into a multi-week compliance firefight. The reasons applications stall are almost always predictable. And the timeline Health Canada expects you to follow is shorter than most operators realize.

Here’s how it actually works: the regulatory requirements behind the DEL, the submission timeline, the fee structure under the current cost-recovery model, and the documentation gaps that most commonly cause applications to get flagged or rejected.

What the Food and Drug Regulations Actually Require

A Drug Establishment Licence is mandatory under Part C, Division 2 (C.01A) of the Food and Drug Regulations for any establishment in Canada that fabricates, packages, labels, tests, imports, or distributes Schedule C or Schedule D drugs — or any drug subject to national standards. That includes prescription pharmaceuticals, biologics, and drugs sold under a Drug Identification Number (DIN). If your operation touches those product categories, you need a DEL, and it renews every 12 months.

The statutory requirement is straightforward: apply for renewal before expiry. What the regulation doesn’t specify is how far in advance. That’s where operators get into trouble.

Section C.01A.009 also requires that DEL holders notify Health Canada within 30 days of any change to the information in their licence application. Personnel changes, facility modifications, new activity classes, changed contract arrangements — all of it triggers a notification obligation. Many facilities miss this in the ordinary course of operations: a new Quality Person gets appointed, a contract testing lab is swapped out, a secondary packaging line gets added. When those changes haven’t been reported and they surface during renewal review, they create discrepancies that reviewers are required to resolve before the licence can be renewed.

The practical takeaway: DEL compliance isn’t a once-a-year event. The change notification requirement means your file with Health Canada should be current 365 days a year.

The Renewal Timeline Health Canada Doesn’t Advertise Clearly

The unofficial industry standard — and Health Canada’s own recommendation in practice — is to submit your DEL renewal application at least 60 days before expiry. You’ll find references to this in guidance communications and regulatory workshops, though it’s not prominently codified in a single document the way practitioners would prefer.

The reason 60 days is necessary: Health Canada’s service standard for processing a complete DEL renewal application is approximately 30 business days from receipt. That word “complete” carries significant weight. If reviewers flag missing documentation, an unresolved inspection observation, or a discrepancy in your site information, the clock pauses while you respond. A single deficiency cycle — request, response, review — can consume 3 to 4 weeks on its own.

Renewals are submitted through the Drug and Health Product Portal (DHPP), Health Canada’s electronic submission platform. Portal access requires a configured account with appropriate user roles. This is a detail that trips up operators who’ve had staff turnover in their regulatory function: if the person who managed DHPP access has moved on and credentials weren’t transferred, re-establishing access can take days — days that aren’t available when you’re already running close to expiry.

One more timing consideration: if your application is complete and under active review when your licence expiry date arrives, Health Canada does have administrative discretion to maintain your status while the review is finalized. But that’s a narrow administrative accommodation, not a published policy, and it’s not something to build your timeline around. Treating it as a backup strategy tends to surface in inspection observations about regulatory compliance management.

DEL Fees: Understanding the Cost-Recovery Model

Health Canada operates on a cost-recovery fee structure for DEL applications, governed by the Health Products Fees Regulations (SOR/2021-43), which came into force in April 2021 and replaced the prior fee schedule. The current model is tiered by activity class — what you do at your facility determines what you pay, and sites holding multiple activity classes pay for each one.

The six primary activity classes for DEL purposes are: fabrication, packaging/labelling, testing, importation, distribution, and wholesale. A mid-sized operation licensed for fabrication, in-house testing, and importation is paying across three separate activity classes. Combined annual fees for that kind of multi-activity licence can exceed $15,000 CAD, depending on the current schedule. That figure isn’t static — Health Canada adjusts fees annually for inflation under the Regulations.

A few billing mechanics that regularly catch operators off guard:

Invoices come after submission, not before. You submit your renewal application first, Health Canada processes it to the point of approval, and then issues the fee invoice. Payment is required before the renewed licence is actually issued. Operators who aren’t tracking their accounts receivable carefully can find themselves surprised by an invoice arriving with a short payment window.

Fees are non-refundable once processing has begun. If you withdraw an application after review has started — or if it’s rejected — you don’t get that money back. That creates a real incentive to submit complete, accurate applications the first time.

Outstanding balances block renewal. Any unpaid fees from prior licence periods, including late payment charges, will prevent Health Canada from issuing a renewed licence. If your fee account has a discrepancy from a prior year that wasn’t noticed at the time, it will surface now.

The current fee schedule is published on Health Canada’s website and updated annually. If you’re budgeting for renewal, pull the current schedule rather than relying on what you paid the prior year — the figures may differ.

The Most Common Reasons DEL Renewals Get Flagged

Health Canada typically issues a Notice of Deficiency (NOD) rather than an outright rejection — you receive a specified response period to address the identified issues. But if deficiencies aren’t resolved within that window, the practical outcome is the same: no renewed licence. The most common reasons applications hit that wall are consistent enough to be worth cataloguing.

Unresolved GMP inspection observations. This is the biggest one. If your most recent Health Canada GMP inspection ended with a Non-Compliant rating, or with a Compliant — Corrective Action Required outcome where your CAPA responses haven’t been accepted, that compliance status is visible to the DEL programme. Health Canada’s Inspection Directorate and the DEL licensing function share data. A CAPA plan with no demonstrated implementation progress is a renewal risk, period.

Undisclosed changes to site operations. If you added a new manufacturing activity, changed your physical location, restructured your quality organization, or modified your contract testing arrangements and didn’t submit the required C.01A.009 change notification at the time, the discrepancy will appear during renewal review. Resolving it retroactively requires supplemental filings and sometimes explanatory documentation, adding weeks to the timeline.

An outdated or internally inconsistent Site Master File. The SMF submitted with your DEL must accurately reflect your current operations. Equipment references pointing to decommissioned instruments, QA org charts showing staff who left 18 months ago, or process descriptions that don’t align with your current SOPs — these are document control flags that reviewers will act on.

Quality Person designation issues. Section C.01A.006 of the Food and Drug Regulations requires every DEL holder to designate a Quality Person who meets defined qualification criteria. If your designated QP left and the change wasn’t formally reported, or if the successor doesn’t meet the regulatory criteria, the gap needs to be resolved before renewal can proceed. This is more common than it should be — QP turnover happens fast, and regulatory notification often lags behind the operational reality.

Incomplete compliance with earlier regulatory commitments. If a prior renewal was issued with conditions — a required corrective action, a mandatory follow-up inspection, a commitment to file amended documentation — and those conditions aren’t closed out, your current file isn’t clean.

GMP Compliance as the Thread Running Through Every Renewal

Here’s what isn’t always communicated clearly: a DEL renewal is not simply an administrative form. It’s a compliance attestation. When you submit, you are formally affirming that your operations remain compliant with Health Canada’s GUI-0002 — the Good Manufacturing Practices Guidelines — and with the applicable provisions of the Food and Drug Regulations.

Health Canada inspects DEL holders on a risk-stratified cycle. Higher-risk manufacturing categories — sterile products, biologics, clinical trial materials — see inspection visits more frequently, sometimes every 2 to 3 years. Lower-risk wholesale and distribution operations may go 5 or more years between formal inspections. But the inspection cycle and the annual renewal cycle run independently of each other. You renew every year regardless of whether an inspection happened that year.

What this means in practice: in years without an inspection, your internal compliance posture is still directly relevant to renewal. If a Health Canada inspector arrives six months after renewal and finds deviations that were clearly present at the time of your attestation, you’re not just handling an inspection observation — you’re dealing with a question about the accuracy of your renewal submission itself.

Health Canada has formally endorsed the ICH Q10 Pharmaceutical Quality System framework, which treats change control, CAPA, and management review as continuous operational processes rather than inspection-triggered events. Facilities that internalize that approach — running quality system reviews quarterly, not annually — consistently find that DEL renewal is a confirmation of work already done, not a scramble to assemble documentation that should have been current all along.

Getting the Renewal Right Without the Last-Minute Scramble

The conditions for a clean DEL renewal come down to five elements: a current and accurate Site Master File, documented closure of all prior inspection observations, a confirmed and compliant Quality Person designation, a clear fee account with no outstanding balances, and submission at least 60 days before expiry.

Operators who build a quarterly compliance review rhythm — checking their DEL file at the 9-month, 6-month, and 3-month marks, then submitting at 60 days — consistently avoid the situations that turn a standard renewal into a months-long negotiation with Health Canada. And when a facility change, a QP transition, or an inspection outcome complicates the picture, having that lead time is the difference between managing the complexity and being managed by it.

If you’re approaching renewal while also navigating a facility expansion, a new activity class, or an active inspection cycle, the interdependencies multiply quickly. That’s precisely when external regulatory support tends to earn its cost back in days, not months.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025-accredited pharmaceutical and supplement testing for Canadian GMP packages — Qalitex Laboratories provides analytical testing reports and COAs that support DEL documentation requirements across multiple activity classes.
• EU GMP compliance and product licensing for manufacturers expanding into European markets — Care Europe guides Canadian manufacturers through EU regulatory requirements when distribution strategy extends beyond Canada’s borders.